Bullish
Abbott Laboratories recently released its first-quarter 2025 results and updated its guidance, highlighting the continued importance of medical device...
Bearish
A former Abbott Laboratories worker, Ryan Lisowski, is suing the company, alleging he was fired over a Teams chat started by a coworker, Abeygail Stee...
Bullish
Abbott Laboratories has shown solid quarterly results and is expanding its diabetes technology portfolio, specifically with its FreeStyle Libre contin...
Abbott Laboratories (ABT) stock has seen a significant decline over the past year, but a recent analysis by Simply Wall St suggests it may now be unde...
Bullish
The North Dakota State Investment Board recently acquired a new stake of 59,377 shares in Abbott Laboratories, valued at approximately $7.44 million. ...
Bullish
Abbott Laboratories reported higher Q1 2026 earnings and raised its full-year guidance, driven by strong growth in its diabetes care business, particu...
Bullish
Abbott Laboratories recently reported its latest quarterly figures, highlighting continued growth in its medical device and diabetes care business, pa...
Abbott Laboratories recently reported Q1 2026 results that surpassed sales and earnings expectations and completed a US$21 billion acquisition of Exac...
Bearish
A class action lawsuit has been filed against Abbott Diabetes Care Inc. and Abbott Laboratories, alleging their FreeStyle Libre 2 glucose monitors are...
Bearish
Abbott Laboratories is facing a new securities class action lawsuit alleging it concealed FDA health and safety violations at its infant formula facil...
Bullish
Abbott Laboratories (ABT) is presented as a potentially attractive investment due to its high free cash flow yield of 5.1%, strong operating margin of...
Bullish
This article suggests that investors looking for better value and growth than Abbott Laboratories (ABT) stock should consider ResMed (RMD) and Medtron...
Bullish
The global immunoassay market, valued at US$ 22,908.12 million in 2021, is projected to reach US$ 51,503.53 million by 2031, growing at a CAGR of 8.6%...
Bearish
Abbott Laboratories (ABT) stock experienced a 2.29% drop, trading at $87.42, and is significantly below its key moving averages, indicating strong bea...
Neutral
PKO Investment Management Joint Stock Co lessened its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 38.6% during the fourth quarter, accord...
Bullish
CENTRAL TRUST Co reduced its stake in Abbott Laboratories (NYSE:ABT) by 10.2% in Q4 2026. Despite this, insiders have been net buyers of the stock, an...
Bullish
Abbott Laboratories (NYSE: ABT) is highlighted as a compelling dividend stock, with its shares currently down 30% over the past year. Despite recent c...
Bullish
Abbott Laboratories (ABT) has received FDA clearance and CE Mark for its Ultreon™ 3.0 Software, an AI-powered imaging platform. This software integrat...
Abbott Laboratories director Kevin T. Conroy was granted 2,286 restricted stock units under the company's 2026 Incentive Stock Program. This award is ...
ABBOTT LABORATORIES director Daniel J. Starks increased his holdings through an open-market purchase of 10,000 common shares at $92.6537 each and rece...